Long-Term Effectiveness and Safety of Proactive Therapeutic Drug Monitoring of Infliximab in Children with Inflammatory Bowel Disease
Author Information
Author(s): Clemente Bautista Susana, Segarra Cantón Óscar, Padullés-Zamora Núria, García García Sonia, Álvarez Beltrán Marina, Larrosa García María, Cabañas Poy Maria Josep, Sanz-Martínez Maria Teresa, Vázquez Ana, Gorgas Torner Maria Queralt, Miarons Marta
Primary Institution: Hospital Universitari Vall d’Hebron, Barcelona, Spain
Hypothesis
Does proactive therapeutic drug monitoring improve treatment outcomes compared to reactive monitoring in pediatric patients with inflammatory bowel disease?
Conclusion
Proactive therapeutic drug monitoring did not show significant differences in treatment outcomes compared to reactive monitoring, but both groups had results comparable to other studies.
Supporting Evidence
- Proactive TDM showed no significant differences in treatment outcomes compared to reactive TDM.
- Both groups had results not worse than those reported in other studies.
- Further studies with larger samples are needed to optimize treatment strategies.
Takeaway
This study looked at how well monitoring infliximab levels helps kids with gut problems. It found that both ways of checking levels worked similarly.
Methodology
A descriptive, ambispective, single-centre study of pediatric patients with inflammatory bowel disease who underwent infliximab serum concentration measurements.
Potential Biases
The retrospective nature of the reactive monitoring may introduce bias.
Limitations
The small sample size limited the ability to detect significant differences between proactive and reactive monitoring.
Participant Demographics
The study included 38 pediatric patients, with a mean age of 11.68 years, including 6 patients with very early onset inflammatory bowel disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website